AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02937480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-specific training
Description: The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
Study NCT02937480 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Global stretching, memory exercises, health care orientation
Description: The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
Study NCT02894333 — intervention group
Intervention type: BEHAVIORAL
Intervention: behavioral observation
Study NCT04321902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)
Study NCT01328964 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate
Description: fluticasone propionate 44 mcg
Study NCT01328964 — intervention group
Intervention type: DRUG
Intervention: Budesonide
Description: budesonide
Study NCT01328964 — intervention group
Intervention type: DRUG
Intervention: Montelukast
Description: montelukast
Study NCT04221919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β -Blockers
Description: Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
Study NCT03528551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa pegol
Description: Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
Study NCT03528551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa pegol
Description: Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
Study NCT03528551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa pegol
Description: Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
Study NCT02915224 — intervention group
Intervention type: DRUG
Intervention: Chlorambucil
Description: Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Study NCT02915224 — intervention group
Intervention type: DRUG
Intervention: Obinutuzumab
Description: Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Study NCT02701621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT-AT
Description: Aquatic therapy
Study NCT02701621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: Land-based Therapy
Study NCT01494805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV.sFlt-1
Description: 1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
Study NCT01494805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV.sFlt-1
Description: 1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
Study NCT01494805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (ranibizumab alone)
Description: Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
Study NCT02590055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/docetaxel combination
Study NCT03280459 — intervention group
Intervention type: PROCEDURE
Intervention: robot-assisted cystectomy
Description: Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
Study NCT02665247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-SIP
Description: In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
Study NCT02665247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dream discussion
Description: Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
Study NCT01965353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: - Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
Study NCT01965353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
Study NCT01965353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
Study NCT01965353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
Study NCT04431895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: tofacitinib 5 mg tablet administered twice a day for 6 months
Study NCT03934151 — intervention group
Intervention type: PROCEDURE
Intervention: intracorporeal ileocolic anastomosis
Description: laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag
Study NCT03934151 — intervention group
Intervention type: PROCEDURE
Intervention: extracorporeal ileocolic anastomosis
Description: ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
Study NCT04079634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal warming
Description: Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure
Study NCT04079634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard temperature probe monitoring
Study NCT02136953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
Study NCT02136953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
Study NCT02136953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
Study NCT03477487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Human IL-10 variant transgene in a plasmid DNA vector
Study NCT02032082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbone monoxide
Study NCT04548323 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motor imagery
Description: Subjects will perform motor imagery tasks on the motor gestures of running and walking.
Study NCT04702321 — intervention group
Intervention type: OTHER
Intervention: Procedure: Biospecimen Collection
Description: Collection of saliva, buccal swabs, blood, or other sample adequate for germline DNA extraction
Study NCT04702321 — intervention group
Intervention type: OTHER
Intervention: Procedure: Medical Chart Review
Description: Collection of clinical data
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clonidine
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: glycopyrrolate
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketamine
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: marcaine
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: scopolamine
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: midazolam
Study NCT02410460 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ondansetron
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metoclopramide
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: famotidine
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: desflurane
Study NCT02410460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane
Study NCT03165747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: 8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
Study NCT03165747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo sachets taken orally daily in a single administration.
Study NCT04454931 — intervention group
Intervention type: DEVICE
Intervention: Root® with O3® Regional Oximetry
Description: May help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.~It was aimed to determine the appropriate head height that should be given to patients in order to correct the endotracheal suctioning sequence, which is the most important care application of the neurosurgery patients who are followed up in the intensive care unit after surgery, and the possibility of subsequent disruption of cerebral perfusion. Therefore, cerebral oxygenation status, which is the most important parameter that shows the cerebral perfusion status of patients during and after the application, will be followed up by nurses with a non-invasive cerebral oximeter device.
Study NCT04226417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
Study NCT04226417 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
Study NCT05023122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: vitamin D3 (cholecalciferol) 800 IU QD
Study NCT05023122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: calcium citrate 600 mg QD
Study NCT05023122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: calcium citrate 600 mg QD
Study NCT00221013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: augmented CRRT regimen
Description: We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
Study NCT00221013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: augmented CRRT regimen
Description: We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
Study NCT01143285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and active nutritional support.
Description: The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
Study NCT05108701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Psychotherapy
Description: Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
Study NCT05108701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Psychotherapy
Description: Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
Study NCT03464435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
Study NCT03854331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience program
Description: The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
Study NCT01820663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: A high fat, high protein, low- carbohydrate diet
Study NCT01820663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
Study NCT02001701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal Injection of sulfahexafluoride gas
Description: After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
Study NCT06167941 — intervention group
Intervention type: BIOLOGICAL
Intervention: Lung cancer types
Description: Cancer tissue matched to normal tissue, all from the same patient
Study NCT01163552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Description: Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
Study NCT04668417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link
Description: Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
Study NCT04668417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link
Description: Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
Study NCT04058509 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy
Description: 3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
Study NCT03675568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cultured keratinocyte suspension
Description: A new method for treatment of burn wounds
Study NCT03675568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin Graft
Description: A traditional method for treatment of burn wounds
Study NCT01528410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALFApump removal of ascites
Description: Implanted ALFApump, removing produced ascites according to programmed schedule
Study NCT01528410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large volume paracentesis for removal of ascites
Description: Large volume paracentesis - standard of care, removing ascites according to patient need
Study NCT02121860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Study NCT01661738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Vaccine
Description: 360 subjects were divided into three groups (120 subjects in each group), children (2\~6 years of age), early youth (7\~15 years of age) and adult (16\~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Study NCT04375163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic intense exercise protocol
Description: The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
Study NCT04375163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic intense exercise protocol
Description: The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
Study NCT04375163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage treatment
Description: Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set.
Study NCT02717195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 4-6 mg/day, encapsulated tablets, orally
Study NCT02717195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 15-20 mg/day, encapsulated tablets, orally
Study NCT02717195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 10 mg/day, encapsulated tablets, orally
Study NCT02717195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 20 mg/day, encapsulated tablets, orally
Study NCT04640922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gedea Pessary pHyph
Description: Vaginal tablet
Study NCT04640922 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal tablet
Study NCT01149655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)